Ann: Quarterly Activities Report and Appendix 4C, page-42

  1. 899 Posts.
    lightbulb Created with Sketch. 432
    Amen! Couldn't agree more @Hawk70 As a current holder it's even more painful.

    Yep, the two big issues for me are not having a clear funding pathway, and the lack of IP protection.

    I'm not entirely sure of the genesis of the current NYR-BIO3 compound, but if it comes from Kelly's genistein / Veyonda work -- like earlier patent applications (see: https://patents.google.com/patent/US20200215025A1/en ) then they might have some problems. We'll have to wait another 12 months until the patent is published.

    NYR applied for another patent "Compounds for cancer treatment" at the same time last year, so I suspect it might all be part of the latest genistein / soybean grift.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
33.0¢
Change
-0.010(2.94%)
Mkt cap ! $69.60M
Open High Low Value Volume
34.0¢ 34.3¢ 32.5¢ $195.9K 589.3K

Buyers (Bids)

No. Vol. Price($)
2 14970 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
33.5¢ 20100 1
View Market Depth
Last trade - 15.29pm 25/07/2025 (20 minute delay) ?
NYR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.